This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Patient AdherenceTools that help patients finish TRUMENBA

Pfizer TruSupport offers tools that will help your patients stay on track with TRUMENBA, so you can rest assured they’re protected against MenB.

Your patients value and trust your recommendation. At the time of their first dose, communicate the urgency of dose series completion to your patients and their parents and schedule their next dose appointment.Provider recommendation has been shown to improve vaccination coverage by as much as 41%.1In a recent study, patients with prescheduled flu vaccination appointments were almost 7 times more likely to get vaccinated.2Postcard reminders

Reminder recall programs can help increase awareness to patients who are due a first or subsequent dose of TRUMENBA at an upcoming well visit.

Patients who receive postcard reminders are 40% more likely to get vaccinated.3

Talk to a Pfizer Sales Representative for more information.

Pharmacy locator
  • Online locator that patients can use to find the nearest pharmacy that vaccinates with TRUMENBA
  • Especially helpful for college students who are unable to return to your practice for their next dose of TRUMENBA
How to get TRUMENBA
LoadingMenB=serogroup B meningococcal disease.
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
1-844-439-2571 to learn more about Pfizer TruSupport.
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248 to learn more about Pfizer TruSupport.
References:1. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey—Teen, 2010. Clin Pediatr (Phila). 2013;52(2):162-170. 2. Chapman GB, Li M, Leventhal H, Leventhal EA. Default clinic appointments promote influenza vaccination uptake without a displacement effect. Behav Sci Policy. 2016;2(2):41-50.
 Ordering & inventory with TruSupport

Provides multiple convenient options for ordering TRUMENBA​​​​​​

 View the options Loading Coverage & reimbursement with TruSupport

Streamlines the processes of confirming your patient's coverage for TRUMENBA

Learn how Pfizer streamlines
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3196
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.